LRFN3 Antibody
Code | Size | Price |
---|
PSI-5069-0.02mg | 0.02mg | £150.00 |
Quantity:
PSI-5069-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Images
Documents
Further Information
Additional Names:
LRFN3 Antibody: SALM4, FIGLER1, SALM4, UNQ5865/PRO34192, Leucine-rich repeat and fibronectin type-III domain-containing protein 3, Synaptic adhesion-like molecule 4
Application Note:
LRFN3 antibody can be used for detection of LRFN3 by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in mouse samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in mouse samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Background:
LRFN3 Antibody: LRFN3 is one of a family of five transmembrane glycoproteins that are highly expressed in neuronal tissues. LRFN proteins share leucine-rich repeat (LRR)-immunoglobulin-like (Ig)-fibronectin type III (Fn)-transmembrane domain structure with other members of the LRR-Ig-Fn protein superfamily such as the Slitrk family of proteins. Expression of LRFN1, -3, and -4 mRNA was detected in embryonic neuronal cells, while Lrfn2 and Lrfn5 expression was primarily restricted to more mature cells. LRFN1, -2, and -4 bound to PDZ domains of postsynaptic PSD95, re-distributing PSD95 to the cell periphery. It has been suggested that the Lrfn proteins play a role in the developing and/or mature vertebrate nervous system.
Background References:
- Morimura N, Inoue T, Katayama K, et al. Comparative analysis of structure, expression and PSD95-binding capacity of Lrfn, a novel family of neuronal transmembrane proteins. Gene2006; 380:72-83.
- Kobe B and Kajava AV. The leucine-rich repeat as a protein recognition motif. Curr. Opin. Struct. Biol.2001; 11:725-32.
- Aruga J and Mikoshiba K. Identification and characterization of Slitrk, a novel transmembrane protein family controlling neurite outgrowth. Mol. Cell Neurosci.2003; 24:117-29.
Buffer:
LRFN3 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Bovine: (93%)
Immunogen:
LRFN3 antibody was raised against a 16 amino acid synthetic peptide near the center of human LRFN3.
The immunogen is located within amino acids 380 - 430 of LRFN3.
The immunogen is located within amino acids 380 - 430 of LRFN3.
NCBI Gene ID #:
79414
NCBI Official Name:
leucine rich repeat and fibronectin type III domain containing 3
NCBI Official Symbol:
LRFN3
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
NP_078785
Protein GI Number:
13375646
Purification:
LRFN3 Antibody is affinity chromatography purified via peptide column.
Research Area:
Neuroscience
SPECIFICITY:
This antibody is predicted to not cross-react with other members of the LRFN family.
Swissprot #:
Q9BTN0
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
Product Name | Product Code | Supplier | LRFN3 Peptide | PSI-5069P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|